Agenda:

8:00 am – 8:30 am | WELCOME & INTRODUCTION 
Dr. Keith Horspool, VP, Pharmaceutics, Boehringer Ingelheim
Dr. Cornell Stamoran, Founder, Catalent Institute

8:30 am – 9:05 am | IMPORTANCE OF API CHARACTERIZATION FOR IMPROVING DEVELOPABILITY OF SMALL MOLECULES 
Dr. Fredrik Nordstrom, Sr. Principal Scientist, Boehringer Ingelheim 

9:05 am – 9:40 am | MODELING THE PHARMACOKINETIC CHALLENGES OF ORAL SMALL MOLECULE DRUGS 
Dr. Wei Zhu, Associate Principal Scientist, Merck

9:40 am – 10:15 am | FORMULATION STRATEGIES TO OVERCOME ORAL BIOAVAILABILITY CHALLENGES OF SMALL MOLECULE DRUGS 
Mr. Stephen Tindal, Director, Science & Technology. Catalent Pharma Solutions

10:15 am – 10:30 am | BREAK

10:30 am – 11:30 am | AUDIENCE APPLIED LEARNING CHALLENGE- PART 1 AM

11:30 am – 1:00 pm | NETWORKING LUNCH & MEET THE EXPERTS

1:00 pm – 1:35 am | CMC AND QUALITY CONSIDERATIONS 
Mr. Jim Spavins, SVP, Pharm Sci (Ret.), Pfizer; Principal, ‎Spavins Consulting LLC

1:35 pm – 2:10 pm | INSIGHTS AND STRATEGIES TO INCORPORATE PATIENT FOCUSED DESIGN 
 Dr. Cornell Stamoran, Founder, Catalent Institute

2:10 pm – 2:45 pm | STRATEGIES FOR PROGRESSING TO PHASE I FORMULATIONS TO IMPROVE YOUR SPEED TO AND SUCCESS IN THE CLINIC 
TBD

2:45 pm – 3:00 pm | BREAK

3:00 pm – 4:00 pm | AUDIENCE APPLIED LEARNING CHALLENGE- PART 2 PM
Dr. Keith Horspool, VP, Pharmaceutics, Boehringer Ingelheim
Dr. Ronak Savla, Scientific Affairs Manager, Catalent Pharma Solutions